David A. Siegel Prelude Therapeutics Inc Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 50,900 shares of PRLD stock, worth $105,362. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,900
Previous 70,200
27.49%
Holding current value
$105,362
Previous $332,000
41.87%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding PRLD
# of Institutions
62Shares Held
33.9MCall Options Held
400Put Options Held
100-
Orbimed Advisors LLC San Diego, CA10.9MShares$22.6 Million1.0% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$21 Million0.51% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4.13MShares$8.56 Million0.33% of portfolio
-
Boxer Capital, LLC San Diego, CA2.57MShares$5.32 Million0.54% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$2.21 Million0.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $75.3M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...